Literature DB >> 27940517

Tau Positron Emission Tomography Imaging.

Hartmuth C Kolb1, José Ignacio Andrés2.   

Abstract

Alzheimer's disease (AD) is a chronic neurodegenerative disorder and the most common cause of dementia among the elderly population. The good correlation between the density and neocortical spread of neurofibrillary tangles (NFTs) and the severity of cognitive impairment offers an opportunity to use a noninvasive imaging technique such as positron emission tomography (PET) for early diagnosis and staging of the disease. PET imaging of NFTs holds promise not only as a diagnostic tool but also because it may enable the development of disease-modifying therapeutics for AD. In this review, we focus on the structural diversity of tau PET tracers, the challenges related to identifying high-affinity and highly selective NFT ligands, and recent progress in the clinical development of tau PET radioligands.
Copyright © 2017 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27940517      PMCID: PMC5411699          DOI: 10.1101/cshperspect.a023721

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Biol        ISSN: 1943-0264            Impact factor:   10.005


  12 in total

Review 1.  A Brief Overview of Tauopathy: Causes, Consequences, and Therapeutic Strategies.

Authors:  Miranda E Orr; A Campbell Sullivan; Bess Frost
Journal:  Trends Pharmacol Sci       Date:  2017-04-25       Impact factor: 14.819

2.  Astrocyte-secreted glypican-4 drives APOE4-dependent tau hyperphosphorylation.

Authors:  Sivaprakasam R Saroja; Kirill Gorbachev; Tcw Julia; Alison M Goate; Ana C Pereira
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-15       Impact factor: 12.779

3.  Worsening hearing was associated with higher β-amyloid and tau burden in age-related hearing loss.

Authors:  Mengmeng Zheng; Jiangyu Yan; Wenjuan Hao; Yuan Ren; Ming Zhou; Yunzhi Wang; Kai Wang
Journal:  Sci Rep       Date:  2022-06-21       Impact factor: 4.996

4.  Evaluation of [18F]-N-Methyl lansoprazole as a Tau PET Imaging Agent in First-in-Human Studies.

Authors:  Vasko Kramer; Allen F Brooks; Arlette Haeger; Rodrigo O Kuljis; Waqas Rafique; Robert A Koeppe; David M Raffel; Kirk A Frey; Horacio Amaral; Peter J H Scott; Patrick J Riss
Journal:  ACS Chem Neurosci       Date:  2020-01-15       Impact factor: 4.418

5.  An updated radiosynthesis of [18F]AV1451 for tau PET imaging.

Authors:  Andrew V Mossine; Allen F Brooks; Bradford D Henderson; Brian G Hockley; Kirk A Frey; Peter J H Scott
Journal:  EJNMMI Radiopharm Chem       Date:  2017-06-06

Review 6.  Molecular biomarkers of Alzheimer's disease: progress and prospects.

Authors:  Tammaryn Lashley; Jonathan M Schott; Philip Weston; Christina E Murray; Henny Wellington; Ashvini Keshavan; Sandrine C Foti; Martha Foiani; Jamie Toombs; Jonathan D Rohrer; Amanda Heslegrave; Henrik Zetterberg
Journal:  Dis Model Mech       Date:  2018-05-08       Impact factor: 5.758

Review 7.  Molecular Imaging of Tau Protein: New Insights and Future Directions.

Authors:  Rocco Pizzarelli; Natalia Pediconi; Silvia Di Angelantonio
Journal:  Front Mol Neurosci       Date:  2020-12-15       Impact factor: 5.639

8.  Cryo-EM structures of tau filaments from Alzheimer's disease.

Authors:  Anthony W P Fitzpatrick; Benjamin Falcon; Shaoda He; Alexey G Murzin; Garib Murshudov; Holly J Garringer; R Anthony Crowther; Bernardino Ghetti; Michel Goedert; Sjors H W Scheres
Journal:  Nature       Date:  2017-07-05       Impact factor: 49.962

Review 9.  PET Radiopharmaceuticals for Alzheimer's Disease and Parkinson's Disease Diagnosis, the Current and Future Landscape.

Authors:  Bright Chukwunwike Uzuegbunam; Damiano Librizzi; Behrooz Hooshyar Yousefi
Journal:  Molecules       Date:  2020-02-21       Impact factor: 4.411

Review 10.  Positron Emission Tomography (PET) and Neuroimaging in the Personalized Approach to Neurodegenerative Causes of Dementia.

Authors:  Maria Ricci; Andrea Cimini; Agostino Chiaravalloti; Luca Filippi; Orazio Schillaci
Journal:  Int J Mol Sci       Date:  2020-10-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.